Treatment News
Compiled by Gus Cairns
Abacavir implicated in heart attacks
Using the drug abacavir (Ziagen®, also in Kivexa®) seems to nearly double the risk of heart attack, at least while patients stay on it, a study has found. The drug ddI (didanosine, Videx®) also raises the risk, by about 45%.
Read More
Gay men with HIV have near-normal death rates
A study of HIV patients in 24 countries by the UK Medical Research Council has found that gay men who don’t allow their CD4 counts to drop below 350 now have
near normal death rates compared to
the general population, even
off treatment.
Read More
One shot a month – the next stage in HIV therapy?
With a good choice of HIV therapy now available, and resistance rates going down rather than up, what’s the next stage in creating HIV treatment that’s easier to take?
Read More
Resistance rates tumble – but there may be more there than meets the eye
The Retrovirus Conference heard good news on HIV drug resistance. Rates of resistance are falling, both in terms of the proportion of patients who catch drug-resistant HIV, and the proportion who develop it on treatment.
Read More
Does undetectable mean uninfectious?
A group of Swiss scientists recently said that a person with HIV who’s got a consistently undetectable viral load can’t transmit it. What’s the evidence for this? Are there exceptions? And what might the consequences be?
Gus Cairns reports.
Read More |